Abstract:
PURPOSE: A composition with Nelumbinis Semen extracts as an active ingredient for promoting the differentiation of adipocyte in human mesenchymal stem cell is provided to promote differentiating the adipocyte from a human mesenchymal stem cell to produce lipid droplet, enhance the electricity and the volume of skin and reduce wrinkles. CONSTITUTION: A composition for skin external application for promoting the differentiation of adipocyte contains Nelumbinis Semen extracts as an active ingredient. The composition promotes differentiating adipocyte from a mesenchymal stem cell. The mesenchymal stem cell is a human mesenchymal cell. The composition increases adipocyte tissue. For the total weight of the composition, a Nelumbinis Semen extract weighs ranging from 0.001 to 30%. The composition enhances the volume of skin and the elasticity of skin, and reduces skin wrinkles. A pharmaceutical composition for promoting the differentiation of a adipocyte cell contains Nelumbinis Semen as an active ingredient. A Nelumbinis Semen extract is administered from 0.001mg /kg /day-2000mg /kg /day. [Reference numerals] (AA) Relative revelation amount; (BB) Negative control group; (CC) Ligustri Fructus; (DD) Veratri Rhizoma Et Radix; (EE) Forsythiae Fructus; (FF) Nelumbo semen
Abstract:
PURPOSE: A composition containing miRNA molecule or mimic of DUOX2 for controlling skin cell differentiation is provided to regulate DUOX2, filagrin, loricrin, keratin 1, and keratin 10 genes. CONSTITUTION: A composition for controlling skin cell differentiation contains miRNA molecule or mimic of DUOX2 having 7-25 bases with a base sequence of sequence number 1. The miRNA molecule or mimic targets 1358th to 1364th nucleic acids of DUOX2 mRNA 3'-UTR. The composition promotes skin cell differentiation. A miRNA inhibitor of DUOX2 targets 1358th to 1364th nucleic acids of DUOX2 mRNA 3'-UTR. The composition suppresses skin cell differentiation. The skin cell is keratinocytes.
Abstract:
PURPOSE: A composition containing tripeptides, low molecular hyaluronic acid, mineral, and vitamin is provided to enhance stemness of adipose-derived stem cells. CONSTITUTION: A composition for enhancing stemness of adipose-derived stem cells contains 0.001-3 wt% of tripeptide of glycine-proline-hydroxyproline(Gly-Pro-Hyp), 0.01-50 wt% of low molecular hyaluronic acid, 0.001-3 wt% of mineral, and 0.001-3 wt% of vitamin as active ingredients. The composition is designed from ECM(extracellular matrix). The stem cell is human adipose derived stem cells(hADSCs).
Abstract:
PURPOSE: A composition containing ortho-dihydroxyisoflavone derivative for improving skin regeneration or skin elasticity is provided to induce proliferation of epidermal keratinocyte stem cells. CONSTITUTION: A composition for improving skin regeneration or skin elasticity contains 0.001-30 weight% of ortho-dihydroxyisoflavoen derivative of 4',7,8-trihydroxyisoflavone, 4',6,7-trihydroxyisoflavone, or 3',4',7-trihydroxyisoflavone as an active ingredient. An external use skin composition, pharmaceutical composition, or cosmetic composition contains the composition.
Abstract:
PURPOSE: A composition containing herb extract for skin care or plasty is provided to promoter differentiation of mesenchymal stem cells to adipocytes. CONSTITUTION: A composition for promoting differentiation to adipocytes contains Cinnamomum cassia extract as an active ingredient. The composition increases fat tissue. The mesenchymal stem cells are human bone marrow stem cells.
Abstract:
PURPOSE: A screening method of a skin improvement material is provided to effectively screen the skin improvement material capable of preventing skin ageing, maintaining skin moisture, and improving skin barrier function. CONSTITUTION: A screening method of a skin improvement material comprises the following steps: processing a candidate material to a skin cell; detecting an expression amount change of MAP17(membrane-associated protein 17kd); and selecting the candidate material which induces the change of the expression amount as the skin improvement material. The skin cell is a skin keratinocyte.
Abstract:
PURPOSE: A composition for suppressing differentiation and growth of adipocytes is provided to treat or prevent circulatory system disease or ischemic heart disease. CONSTITUTION: A composition for suppressing differentiation or growth of adipocytes contains 0.00001 to 15 weight% of chemerin. The adipocyte is human bone marrow mesenchymal stem cell. A pharmaceutical composition is used in the form of oral administration formulation or injection. The oral administration formulation is formulated in capsule, tablet, suspension, syrup or powder. A functional health food composition for preventing or treating diabetes, hyperlipidemia, hypercholesterolemia, circulatory system diseases contains 0.00001-10 weight% of chemerin. The health food is used in the form of caramel, chocolate, diet bar or snack. A cosmetic composition for treating obesity contains 0.00001-10 weight% of chemerin as an active ingredient. The cosmetic composition is used in the form of massage cream, body lotion, body cream, body oil, or body essence.
Abstract:
PURPOSE: A composition containing pharbitidis seed, Anthriscs aemula Schisch and their mixture for body sliming is provided to suppress adipocyte differentiation and reduce lipid level. CONSTITUTION: A composition for body sliming contains pharbitidis seed extract, Anthriscs aemula Schisch extract or their mixture as an active ingredient. A composition for suppressing adipocyte differentiation contains the pharbitidis seed extract, Anthriscs aemula Schisch extract or their mixture as an active ingredient. Mesenchymal stem cells from human bone marrow are differentiated to adipocytes. The composition for sliming is used in the form of cosmetic composition, health food or pharmaceutical composition.
Abstract:
A pharmaceutical composition regulating the activity of sphingosylphosphorylcholine(SPC) is provided to regulate cell proliferation, inflammation and pruritus and treat inflammmatin or pruritus of dermatitis such as atopic dermatitis. A pharmaceutical composition which regulates the activity of sphingosylphosphorylcholine(SPC) comprises a compound of the chemical formula 1 or its pharmaceutically allowable salt. In the chemical formula 1, X is O or S, Y is CH2 or carbonyl. R1 is hydrogen or C1-10 alkyl, R2 is hydrogen or methyl, but when X is O, either R1 or R2 cannot be hydrogen, R3 is C1-4 alkyl. A method for manufacturing a compound of the chemical formula 1a comprises: a step of reacting a compound of the chemical formula 2 and a compound of the chemical formula 3 under the presence of base to obtain a compound of the chemical formula 4; a step of stirring the compound of the chemical formula 4 under the presence of base to obtain a compound of the chemical formula 5; and a step of performing the peptide bond between the compound of the chemical formula 5 and a compound of the chemical formula 6 to obtain the compound of the chemical formula 1a.